Markets:

Overview

News

Currencies

International

Treasuries

Globus Medical, Inc. Class A Common Stock (NY:GMED)

78.58 -1.20 (-1.50%)

Streaming Delayed Price Updated: 3:36 PM EDT, Jun 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Globus Medical, Inc. Class A Common Stock

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Wells Fargo Maintains Overweight Rating for Globus Medical: Here's What You Need To Know ↗

December 12, 2022

Via Benzinga

2 Bear Market Stocks That Can Make You Richer in 2022 and Beyond ↗

December 09, 2022

A bear market can present fresh opportunities for long-term investors.

Via The Motley Fool

Globus Medical (GMED) Q3 2022 Earnings Call Transcript ↗

November 08, 2022

GMED earnings call for the period ending September 30, 2022.

Via The Motley Fool

Globus Medical Reports Third Quarter 2022 Results

November 08, 2022

From Globus Medical

Via GlobeNewswire

Globus Medical's Earnings Outlook ↗

November 07, 2022

Globus Medical (NYSE:GMED) is set to give its latest quarterly earnings report on Tuesday, 2022-11-08. Here's what investors need to know before the announcement. Analysts estimate that Globus Medical...

Via Benzinga

Globus Medical Schedules Third Quarter Earnings Release and Conference Call

October 19, 2022

From Globus Medical

Via GlobeNewswire

Analyst Ratings for Globus Medical ↗

October 12, 2022

Within the last quarter, Globus Medical (NYSE:GMED) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 18, 2022 ↗

October 18, 2022

Upgrades

Via Benzinga

Analyst Ratings for Globus Medical ↗

August 05, 2022

Globus Medical (NYSE:GMED) has observed the following analyst ratings within the last quarter:

Via Benzinga

What 5 Analyst Ratings Have To Say About Globus Medical ↗

July 15, 2022

Globus Medical (NYSE:GMED) has observed the following analyst ratings within the last quarter:

Via Benzinga

What 6 Analyst Ratings Have To Say About Globus Medical ↗

May 11, 2022

Analysts have provided the following ratings for Globus Medical (NYSE:GMED) within the last quarter:

Via Benzinga

Globus Medical Issues Softer Outlook For Q1, CEO Resigns ↗

April 22, 2022

Via Benzinga

Where Globus Medical Stands With Analysts ↗

March 28, 2022

Analysts have provided the following ratings for Globus Medical (NYSE:GMED) within the last quarter:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 12, 2022 ↗

October 12, 2022

Upgrades

Via Benzinga

Expert Ratings for Globus Medical ↗

October 11, 2022

Analysts have provided the following ratings for Globus Medical (NYSE:GMED) within the last quarter:

Via Benzinga

Short Volatility Alert: Globus Medical, Inc. ↗

August 26, 2022

On Thursday, shares of Globus Medical, Inc. (NYSE: GMED) experienced volatile short activity. After the activity, the stock price went up +1.83% to $62.78. The overall sentiment for GMED has been...

Via Benzinga

Globus Medical Earnings Perspective: Return On Invested Capital ↗

August 18, 2022

Via Benzinga

Globus Medical's Return On Invested Capital Insights ↗

June 10, 2022

Pulled from Benzinga Pro data, Globus Medical (NYSE:GMED) posted Q1 earnings of $38.08 million, an increase from Q4 of 152.11%. Sales dropped to $230.55 million, a 7.79% decrease between quarters.

Via Benzinga

Globus Medical: Q1 Earnings Insights ↗

May 10, 2022

Globus Medical (NYSE:GMED) reported its Q1 earnings results on Tuesday, May 10, 2022 at 04:15 PM. Here's what investors need to know about the announcement. Earnings Globus Medical missed estimated...

Via Benzinga

55 Biggest Movers From Friday ↗

April 25, 2022

Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 100.9% to close at $2.27 on Friday. Vallon Pharmaceuticals engaged Ladenburg Thalmann & Co Inc to evaluate...

Via Benzinga

Globus Medical's Q4 Earnings Beat Estimates, But FY22 Outlook Lags ↗

February 18, 2022

Globus Medical Inc's (NYSE: GMED) Q4 sales rea

Via Benzinga

Globus Medical: Q4 Earnings Insights ↗

February 17, 2022

Globus Medical (NYSE:GMED) reported its Q4 earnings results on Thursday, February 17, 2022 at 04:15 PM. Here's what investors need to know about the announcement.

Via Benzinga

Earnings Scheduled For February 17, 2022 ↗

February 17, 2022

Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

April 21, 2022

Gainers

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For March 28, 2022 ↗

March 28, 2022

Upgrades

Via Benzinga

Health Care Stocks Could Use A Surgical Boom — Will It Happen For Stryker, Boston Scientific, Others? ↗

March 15, 2022

Elective procedures are recovering slowly as Covid cases decline. Will they ever boom?

Via Investor's Business Daily

Globus Medical's Return on Invested Capital Insights ↗

February 21, 2022

Pulled from Benzinga Pro data, Globus Medical (NYSE:GMED) showed a loss in earnings since Q3, totaling $15.11 million. Sales, on the other hand, increased by 8.84% to $250.02...

Via Benzinga

Expert Ratings For Globus Medical ↗

February 18, 2022

Within the last quarter, Globus Medical (NYSE:GMED) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total...

Via Benzinga

The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings ↗

February 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Agios's Metabolic Disorder Treatment Receives FDA Approval (NASDAQ: AGIO...

Via Benzinga

The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios ↗

February 17, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Amylyx's ALS Treatment Regulatory Application To Be Reviewed By FDA Panel...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.